Lyell Immunopharma (NASDAQ:LYEL) Trading 5.8% Higher

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price was up 5.8% on Monday . The stock traded as high as $2.36 and last traded at $2.36. Approximately 234,559 shares were traded during trading, a decline of 77% from the average daily volume of 1,004,176 shares. The stock had previously closed at $2.23.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price objective on Lyell Immunopharma from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th.

Lyell Immunopharma Stock Performance

The company has a market capitalization of $612.37 million, a P/E ratio of -2.59 and a beta of -0.56. The stock has a 50 day moving average price of $2.29 and a 200 day moving average price of $2.03.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. As a group, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Several large investors have recently added to or reduced their stakes in LYEL. Vanguard Personalized Indexing Management LLC purchased a new stake in Lyell Immunopharma in the 4th quarter worth about $31,000. RPO LLC purchased a new position in Lyell Immunopharma during the 4th quarter valued at about $38,000. Public Employees Retirement System of Ohio grew its holdings in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company's stock valued at $40,000 after buying an additional 14,229 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Lyell Immunopharma by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company's stock valued at $57,000 after buying an additional 22,701 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Lyell Immunopharma during the 3rd quarter valued at about $80,000. Hedge funds and other institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.